Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Berlin - Delayed Quote EUR

Halozyme Therapeutics Inc (RV7.BE)

Compare
52.12
-1.28
(-2.40%)
At close: April 17 at 8:08:20 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for RV7.BE

Recent News: RV7.BE

View More
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
Simply Wall St. 4 days ago
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
Investor's Business Daily 9 days ago
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
PR Newswire 10 days ago
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
PR Newswire 11 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks 12 days ago
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR Newswire 13 days ago
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
PR Newswire 20 days ago
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Zacks 23 days ago
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
Zacks 25 days ago
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Zacks 27 days ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Zacks 30 days ago
View More

Related Tickers

OSTX OS Therapies Incorporated
1.5300
-2.55%
 
LCTX Lineage Cell Therapeutics, Inc.
0.4100
-1.63%
 
RPRX Royalty Pharma plc
32.60
+1.26%
 
ABEO Abeona Therapeutics Inc.
4.8400
-0.21%
 
TNYA Tenaya Therapeutics, Inc.
0.4500
-2.58%
 
RXRX Recursion Pharmaceuticals, Inc.
5.50
+3.38%